Exchange: NYSEMkt·Updated 07:34 PM EDT
CATX logo

CATXPerspective Therapeutics Inc

$2.82
$0.09
(3.09%)
Today
Closed $2.82
$0.01
(0.35%)
After Hours
EarningsAug 12
Mkt Cap$331.87M
Vol812,765.00
News
all
press releases
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Zacks
More News
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued...
PR Newswire
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...
PR Newswire
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +46.96% and +21.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -9.38% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
>

Advertisement|Remove ads.